Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled hUC-MSC-derived exosomes for ACOS
IRCT20260719070261N1Phase 2Not yet recruiting
- Sponsor
- Iran National Science Foundation
- Start
- Nov 2026
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2 trial of human umbilical cord mesenchymal stem cell-derived exosomes in Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS) (2 arms), sponsored by Iran National Science Foundation. Primary endpoint: Safety and tolerability of the intervention. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
human umbilical cord mesenchymal stem cell-derived exosomes
03
Conditions
Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS)
Beyond the preview
Go deeper on IRCT20260719070261N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260719070261N1.